IDCGS CLINICA DE DIAGNOSTICOS MEDICOS LTDA;BIOCRATES LIFE SCIENCES AG;FUNDAÇÃO PIO XII HOSPITAL DE CANCER DE BARRETOS CNPJ/MF
发明人:
ANDRE LOPES CARVALHO,RENÉ ALOISIO DA COSTA VIERA,ISMAEL DALE COTRIM GUERREIRO DA SILVA,EDSON GUIMARAES LO TURCO,THERESE KOAL
申请号：
US15510080
公开号：
US20170299592A1
申请日:
2015.09.10
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates to a metabolic biomarker set for use in assessing breast cancer in a mammalian subject. In particular, the invention relates to a metabolic biomarker set for screening and/or diagnosing breast cancer, the metabolic biomarker set comprising at least (a) one amino acid selected from glutamine, glutamate and serine, and one lipid, or (b) glutamine and glutamate. Further, the invention relates to a metabolic biomarker set for prediction of therapeutic response to breast cancer neoadjuvant chemotherapy. Further, the invention relates to a metabolic biomarker set for assessing biochemical reflection of breast cancer tumor activity. Further, the invention relates to a metabolic biomarker set for subclassification between intrinsic breast cancer tumor subtypes. Moreover, the present invention relates to a method for assessing breast cancer, which comprises obtaining a biological sample, preferably blood, from a mammalian subject and measuring in the biological sample the amount and/or ratios of metabolites. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess breast cancer.
